摘要
目的 :探讨转人内皮抑素基因双歧杆菌口服制剂对肺癌的治疗效果。方法 :选择肺癌患者 118例 ,比较服用转内皮抑素基因双歧杆菌口服制剂前后患者症状和体征 ,影像学检查 (X线、CT、MRI) ,细胞学检查 ,纤维支气管镜检查及病理活检、免疫学检查 (CEA)和生活质量等方面的变化。结果 :服用转内皮抑素基因双歧杆菌口服制剂后患者症状和体征及生活质量等较服用前均有好转或明显好转 ,肺癌细胞生长被明显抑制。结论 :转内皮抑素基因双歧杆菌口服制剂对肺癌有较好的治疗效果。
Objective:To approach the effect of transgenic Bifidobacteria of endostatin on lung cancer. Methods:One hundred and eighteen patients with lung cancer were randomly selected to study the clinical manifestation, radioassays (X ray,CT,MRI), cytological examination, fiberbronchoscopy, biopsy, immunoassays (CEA) and quality of living (QOL) before and after taking oral transgenic Bifidobacteria of endostatin. Results: Most patients′ symptoms,physical signs and QOL were improved or remarkably improved after taking oral transgenic Bifidobacteria of endostatin. Meanwhile, the growth of lung cancer cells was evidently inhibited. Conclusion:Oral transgenic Bifidobacteria of endostatin have good effect on human lung cancer. [
出处
《南京军医学院学报》
2001年第2期77-79,共3页
Journal of Nanjing Military Medical College
基金
江苏省自然科学基金资助 (BK2 0 0 0 0 0 1)
